Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00600327 · ClinicalTrials.gov registry record · Phase 3

Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™

A Phase 3 study, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 3
Development phase
488
Enrollment target

NCT00600327: Completed Phase 3 study, sponsored by Boston Scientific Corporation.

NCT00600327 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 488 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00600327, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 3
Development phase
488 participants
Enrollment target

Study Summary

The primary objective of this study is to demonstrate the safety of the NexStent for treatment of carotid artery lesions undergoing stenting with adjunctive use of the FilterWire distal embolic protection device. The rates will be compared to an Objective Performance Criterion (OPC) derived from historic data from high-risk patients undergoing surgical intervention with Carotid endarterectomy. Patients included in this study are those at higher risk for complications associated with CEA.

Interventions

  • DEVICE EndoTex™ NexStent™
  • DEVICE Filter Wire EZ™

Trial Details

FieldValue
Enrollment Target 488 participants
Start Date 2001-12
Est. Completion 2007-06
Phase Phase 3
Boston Scientific Corporation

280 total trials

What the finished NCT00600327 record still lists

NCT00600327 is an interventional study that assigns participants to a tested intervention. The registered 488 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (37% lower).

The record links to 0 conditions, and to 2 interventions - of which EndoTex™ NexStent™ is the first listed.

NCT00600327 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00600327 about?

NCT00600327 is a clinical study titled "Carotid Artery Revascularization Using the Boston Scientific EPI Filter Wire EZ™ and the EndoTex™ NexStent™". The primary objective of this study is to demonstrate the safety of the NexStent for treatment of carotid artery lesions undergoing stenting with adjunctive use of the FilterWire distal embolic protection device. The rates will be compared to an Objective Performance Criterion (OPC) derived from his...

What is the current status of trial NCT00600327?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 488 participants. The study started on 2001-12. Estimated completion is 2007-06.

What interventions are being tested in trial NCT00600327?

The interventions under investigation include: EndoTex™ NexStent™ (DEVICE), Filter Wire EZ™ (DEVICE).

Who is sponsoring clinical trial NCT00600327?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00600327's enrollment target sits among peer trials

488 784th of 2000 higher than 1,215 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05154669 · 488 participants · Phase 3

    Integrating Financial Coaching and Smoking Cessation Coaching

  • NCT06532877 · 488 participants · NA

    Telephone Support in Advanced Gastrointestinal Cancer

  • NCT06602479 · 488 participants · Phase 2

    A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

  • NCT06794983 · 488 participants · NA

    Calls and Coordination for Transitions of Care at Re-entry

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00600327, the US trial registry maintained by the National Library of Medicine. NCT00600327 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.